Identification of Prognostic Biomarker Candidates Associated With Melanoma Using High-Dimensional Genomic Data.

Survival of patients with metastatic melanoma varies widely. Melanoma is a highly proliferative, chemo-resistant disease. With the recent availability of immunotherapies such as checkpoint inhibitors, durable response rates have improved but are often still limited to 2-3 years.